Objective: To identify causes of the autosomal-recessive malformation, diencephalic-mesencephalic junction dysplasia (DMJD) syndrome. Methods: Eight families with DMJD were studied by whole-exome or targeted sequencing, with detailed clinical and radiological characterization. Patient-derived induced pluripotent stem cells were derived into neural precursor and endothelial cells to study gene expression. Results: All patients showed biallelic mutations in the nonclustered protocadherin-12 (PCDH12) gene. The characteristic clinical presentation included progressive microcephaly, craniofacial dysmorphism, psychomotor disability, epilepsy, and axial hypotonia with variable appendicular spasticity. Brain imaging showed brainstem malformations and with frequent thinned corpus callosum with punctate brain calcifications, reflecting expression of PCDH12 in neural and endothelial cells. These cells showed lack of PCDH12 expression and impaired neurite outgrowth. Interpretation: DMJD patients have biallelic mutations in PCDH12 and lack of protein expression. These patients present with characteristic microcephaly and abnormalities of white matter tracts. Such pathogenic variants predict a poor outcome as a result of brainstem malformation and evidence of white matter tract defects, and should be added to the phenotypic spectrum associated with PCDH12-related conditions.
W e reported on a new clinical condition, diencephalicmesencephalic junction dysplasia (DMJD), characterized by a distinctive brainstem "butterfly sign" on axial computed tomography (CT)/magnetic resonance (MR) images. Although the genetic basis was not previously known, clinical data suggested a unique developmental brainstem defect. 1 The butterfly sign was attributed to an anterior midbrain cleft contiguous with the third ventricle, along with downward displacement of the diencephalic-mesencephalic junction. In DMJD patients studied with tractography, the corticospinal tract (CST), which originates in the cortical motor area and normally courses medially to project to the contralateral spinal cord, instead coursed laterally and appeared to terminate prematurely. A defect in CST function was clinically evidenced by spasticity of the limbs accompanied by quadriparesis. Additionally, thinned corpus callosum in the majority of subjects supported a white matter tract developmental defect. Since the original publication, several reports of additional patients with DMJD have appeared, [2] [3] [4] suggesting a unique radiographically defined condition, but the genetic basis remained unknown.
Here, we analyzed two of the originally described DMJD families and found biallelic loss-of-function variants in protocadherin-12 (PCDH12). Moreover, we identify six additional families for a total of eight independent families representing 14 patients carrying pathogenic variants in PCDH12. PCDH12 belongs to the nonclustered group of the protocadherin family, the largest group within the cadherin superfamily, 5, 6 encoding an 1,184-amino-acid (aa) glycoprotein with six cadherin domains, a transmembrane domain, and an intracellular domain. PCDH12 was originally identified in endothelioma cell lines, 7 where it concentrates at cell-cell junctions and promotes cell adhesion. 8, 9 Protocadherins are diversified cell-surface proteins with over 70 members that are part of the cadherin superfamily. The protocadherin family is subdivided into the clustered and nonclustered groups based on their genomic organization. 5, 6 Correlated expression patterns of nonclustered protocadherins suggest roles in neural circuit formation, 10, 11 and several nonclustered protocadherin genes have been implicated in neurological diseases. Pathogenic variants in the X-linked PCDH19 cause female-specific epilepsy with mental retardation (MIM#300088). 12,13 PCDH8, -9, and -10 have been linked to autism, [14] [15] [16] 
Patients and Methods

Patient Recruitment
Patients were identified from genetics and/or neurology clinics targeting patients with structural brain diseases or neurodevelopmental disorders in regions of the world displaying elevated rates of parental consanguinity. All patients/families enrolled in institutional review board-approved protocols and provided consent for study. The total cohort includes >6,000 individual families recruited between 2004 and 2017 presenting with features of intellectual disability, autism-related conditions, microcephaly, structural brain disorders, epilepsy, or neurodegeneration. The cohort was enriched for families with recessive pediatric brain disorders attributed to consanguinity (>80% of pedigrees) and multiple affected members (>60% of families). Routine medical records, history, physical and neurological examination, as well as evaluation of brain MR imaging (MRI) or CT were carried out as part of the standard clinic evaluation, and several patients underwent both modes of imaging. Determination of callosal abnormalities was based on visual observation by taking into consideration the age of each patient at the time of imaging. Pedigree analysis and blood sampling were pursued in all families, and subjects were selected for exome sequencing based upon a clinically defined neurodevelopmental genetic condition. Sequencing was performed on 1 or 2 affected patients or the father-mother-affected trio per family.
Exome Sequencing
Genomic DNA (gDNA) was extracted and subjected to exon capture, sequencing, variant calling, and computational filtering as previously described. 22 26 with iPSCs cultured in serum-free floating embryoid body-like aggregates with 1mM of dorsomorphin (Tocris Bioscience, Bristol, United Kingdom), 2mM of A8301 (Tocris), and kept shaking at 95rpm for 7 days. Resultant embryoid bodies (EBs) were plated onto Matrigel-coated (BD Biosciences, San Jose, CA) dishes in neutral buffered formalin (NBF) medium (Dulbecco's modified Eagle's medium/F12, 0.5 × N2, 0.5 × B27, and 20ng/ml of basic fibroblast growth factor) to yield rosettes, which were dissociated with Accutase (Millipore, Burlington, MA) after 5 to 7 days, and resultant NPCs plated onto polyornithine/laminin-coated (POL; Sigma-Aldrich) dishes in NBF medium. Endothelial cells (ECs) were differentiated as previously described, 27 and iPSCs were cultured in serumcontaining media in a nonadherent Petri dish for 13 days. Resultant EBs were dissociated to single cells and incubated with anti-CD31/fluorescein isothiocyanate (BD Pharmingen, San Diego, CA). Fluorescence-activated cell sorting (FACS) analysis to sort CD31 + cells was performed on a FACSAria instrument (BD Biosciences), and resultant CD31 + cells were plated onto 1% gelatin-coated dishes in endothelial growth medium-2 medium (Lonza, Basel, Switzerland). Experiments were performed with NPCs at passages four to six and ECs at passages three to five. Bright field images were taken in an EVOS microscope and processed with Photoshop CS5 (Adobe Systems, San Jose, CA).
Neurite Length Quantification
To determine neurite length, NPCs were plated on POLcoated dishes and transfected with phosphorylated enhanced green fluorescent protein (pEGFP) plasmid using Lipofectamine 2000 (Thermo Fisher Scientific). pEGFP-tagged NPCs were allowed to extend processes, then analyzed after 24 hours. Cells were fixed for 10 minutes with 4% paraformaldehyde, washed with phosphate-buffered saline, permeabilized with 0.15% Triton X-100, and blocked 1 hour in the same solution with 5% normal donkey serum. Slides were incubated with primary antibody (Nestin; 1:2,000; Millipore) overnight at 4 o C and then incubated with fluorescently labeled secondary antibody (Jackson ImmunoResearch, West Grove, PA) for 2 hours at room temperature. Fluorescent signal was detected using an Olympus IX51 inverted microscope (Olympus, Tokyo, Japan) or Leica SP5 confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany), then images were processed with Photoshop CS5 (Adobe). Length of the primary neurite per NPC was measured using FIJI/ImageJ (NIH, Bethesda, MD).
Results
Identification of Pathogenic Variants in PCDH12
In order to identify causes of DMJD, we first studied the originally reported families. 1 We performed whole-exome sequence (WES) analysis from 2 affected individuals in family 1 (originally described as family 1592), with prioritization of variants based upon established criteria 28 and <0.1% allele frequencies derived from an in-house exome database from ethnically matched individuals. We identified six variants of moderate-to-high impact (see Supplementary Table 1 ). Further filtering of variants for only "high impact" identified a single rare homozygous hg19: chr5:141334906delC variant in PCDH12 (c.2511delG), a 1-base-pair (bp) deletion, leading to a frameshift (p.S838fs*; Fig 1A,B) , which segregated according to a recessive mode of inheritance. Sanger sequencing of the coding region of PCDH12 in the affected individuals of previously described family 2 (originally described as family 1846) 1 identified a hg19:chr5: 141334652delAG (c.2765delCT) 2-bp deletion leading to a frameshift (p. P922fs*). Of the three families originally described with DMJD, 1 all displayed evidence of the butterfly sign, families 1 and 2 showed lateral ventricles with typical size, and family 1825 showed massively dilated lateral ventricles. Consistent with that phenotypic difference, in family 1825 no PCDH12 pathogenic variant was identified. The presumed role of PCDH12 in cell-cell contact-dependent recognition made it an attractive candidate for DMJD, prompting further investigation. We identified six additional families with pathogenic variants in PCDH12. WES analysis from our cohort of identified six additional PCDH12 homozygous truncating pathogenic variants. Families 3 and 4 both displayed the homozygous 2-bp deletion (c.2765delCT) present in family 2, and family 5 presented with a nonsense pathogenic variant, hg19:chr5:141336579C>A (c.838G>T), leading to a premature stop codon (p.E280*; Fig 1A,B) . No other prioritized variants segregated in any family (see Fig 1 and  Supplementary Tables 2 and 3) , leaving PCDH12 as the top candidate for each family.
A second cohort of 2,000 subjects with neurodevelopmental disorders from the Yale Mendelian Sequencing Consortium was analyzed with WES and identified two additional consanguineous families with homozygous deleterious variants in PCDH12. Family 6 displayed an hg19: chr5: 1413336965G>A (c.452C>T) variant leading to a p.R151* premature stop codon, and family 7 displayed the same 2-bp deletion (c.2765delCT) found in families 2, 3, and 4. We identified an additional Moroccan Jewish nonconsanguineous family 8 presenting with a homozygous 1-bp deletion hg19:chr5:141336357delC (c.1060delG), p.Val354fs* (Fig 1A,B) . Direct questioning showed no evidence of known shared ancestry for families sharing a common pathogenic variant. No correlation was detected between individual pathogenic variant and overall disease severity. No biases were detected in severity or age of onset based upon patient sex, and all pathogenic variants were fully penetrant without observed phenocopies within the family. Direct Sanger sequence confirmed segregation in all available family members according to strict recessive inheritance with full penetrance. To study the effect of patient pathogenic variants, we used point mutagenesis to introduce c.2765delCT (most common variant), c.2511delG (example frameshift), and c.452C>T (example nonsense) in a plasmid containing full-length PCDH12. We found no protein expression after misexpressing mutated PCDH12 constructs in 293T cells (Fig 1C) . We conclude that the pathogenic variants tested result in lack of PCDH12 expression.
PCDH12 Patients Show Microcephaly and Spasticity
Clinical features of all 14 individuals from the original two families with PCDH12 pathogenic variants and six new families are summarized in the Table and reported in detail in Supplementary Table 4 . Recurrent fever of unknown etiology was observed in 64% of patients, with early onset and up to 2 months of age. Epilepsy was observed in 76% of patients with onset usually before 3 months of age and consisted of tonic, atonic, generalized tonic-clonic, and focal seizures, partially controlled with anticonvulsant medications. History of recurrent vasomotor instability was prominent in more than half of the patients (57%). The study included 10 males and 4 females, and ages ranged from 18 months to 6 years.
All patients presented with microcephaly and profound psychomotor delay. Head circumference was 1.5 to 8.7 standard deviations (SDs) below the mean, with almost 80% of patients (78%) in the range of 3 to 6 SDs below the mean. Head circumference at birth was available in 7 of 14 patients and ranged from 0.6 to 1.5 SDs below the mean, indicating predominantly postnatal progressive microcephaly. Bitemporal narrowing attributed to severe microcephaly was noted in half of patients. None was able to stand or walk independently, and none developed meaningful fine motor skills or language. Most patients displayed severe cognitive impairment, and 28% of patients presented with autistic features. Ataxia was present in 42% of patients. Pyramidal tract signs were evident in all; 64% of patients presented with hyperreflexia whereas the rest displayed truncal hypotonia (28%), and mild-to-severe appendicular spasticity was present in 28% of patients. Cranial nerve findings included strabismus (28% of patients), dysphagia (28% of patients), minimalto-absent tracking of objects (21% of patients), and squinting (14% of patients). A combination of two or even three of these cranial nerve findings was observed in those more severely affected patients (1-V-2, 2-IV-2, and 3-IV-1). Facial dysmorphism was noted in most of patients (85%), which included low-set ears, broad prominent nasal bridge, long flat philtrum, broad chin, and thin upper lip (Fig 1D) . Metabolic profile and echocardiography was normal in all patients evaluated.
Brain imaging was available in 12 of 14 subjects. Five patients underwent only MRI, whereas the other 7 had MRI plus CT head imaging. Brain imaging demonstrated a variety of brainstem malformations present in affected individuals in all families; including the DMJD pathognomonic butterfly-like contour of the midbrain on axial sections (Fig 2) . Thin corpus callosum was frequently observed in patients and did not show more-severe thinning in older patients, arguing against progressive atrophy (Fig 3) . Overall, cerebellum and pons were preserved and ventriculomegaly was present in 57% of patients. Our investigation did not reveal any overt vascular or coagulation phenotypes in patients (Supplementary Table 4) , and MRI showed normal cerebral vascular flow voids, suggesting lack of detectable vascular defect. PCDH12 pathogenic variants have been recently linked to brain calcifications 21 ; therefore, we examined the available CT images. We found subtle brain calcifications in six of seven available CT studies (not shown), suggesting that calcifications can accompany DMJD attributed to PCDH12 mutations.
PCDH12 Is Involved in Neurite Outgrowth
PCDH12 is expressed in several in human tissues, including the nervous system (Fig 4A) , but expression was mainly documented in ECs; therefore, we used iPSCs to determine whether PCDH12 is expressed in human neural cell linages. Fibroblast cultures from 2 affected and 1 carrier individual (heterozygous father) from family 1 were reprogrammed to iPSCs, verified upon expression of pluripotency markers and differentiation to three germ layers (not shown). PCDH12 expression was undetectable in fibroblasts or iPSCs (not shown). Each iPSC line was differentiated into NPCs and ECs separately. All NPC clones expressed early neural stem cell markers PAX6 and nestin. Similarly, all endothelial cell clones expressed the endothelial markers, von Willebrand factor (vWF), calponin, and vinculin (Fig 4B) . PCDH12 showed expression in both neural and endothelial derivative cells. We obtained similar results from NPCs and ECs derived from three different iPSC clones subjected to two independent differentiation rounds for each individual.
PCDH12 was expressed in differentiated cells from control (wild-type) and unaffected (heterozygous) individuals, both in NPCs and ECs, but was undetectable in cells from affected individuals. This is in agreement with the analysis in cell culture (Fig 1C) . Family 1 presented with c.2511delG, a pathogenic variant in the first exon leading to a predicted premature protein truncation, suggesting lack of PCDH12 expression attributed to nonsense mediated decay. Moreover, all neural markers tested were exclusively found in NPCs, from both unaffected and affected individuals. Similarly, ECs from both unaffected and affected individuals expressed endothelial, but not FIGURE 2: Biallelic pathogenic variants in PCDH12 lead to brainstem malformations. Head computed tomography or brain magnetic resonance imaging of 12 affected individuals at the level of midbrain compared to control. All affected individuals showed brainstem malformations (circle). Butterfly sign was most obvious in the originally described families 1 and 2 (top row), consisting of an anterior midbrain cleft contiguous with the third ventricle. In other families in which PCDH12 pathogenic variants were identified from sequencing, the butterfly sign was not obvious (eg, 5 and 8). PCDH12 pathogenic variant in cDNA (c.) and protein (p.) corresponding to NM_016580 and NP_057664 Entrez IDs. cDNA = complementary DNA. neural, markers (Fig 4B) . We conclude that PCDH12 is expressed in both endothelial and neural lineages, and lack of PCDH12 does not notably impact lineage differentiation.
Recently, it has been suggested that nonclustered protocadherins play roles in neurite outgrowth; therefore, we investigated the possible neural phenotypes caused by lack of PCDH12. We utilized dissociated NPCs in culture to investigate the role of PCDH12 in neurite outgrowth. We analyzed morphology of single NPCs plated at high density by sparse GFP labeling (ie, small percent of labeled cells). We found that mutant NPCs showed impaired neurite length (Fig 4C) , suggesting that neurite outgrowth is dependent on PCDH12 expression.
Discussion
Protocadherins are implicated in the establishment and maintenance of neural circuits, and pathogenic variants in some protocadherin genes have been associated with neurodevelopmental and psychiatric disorders. [12] [13] [14] [15] [16] [17] [18] 29 Although recent advances have aided our understanding of the molecular and cellular mechanisms related to protocadherin regulation of functional neuronal circuitry, key questions remain unanswered.
Here, we report on 14 cases in eight families with pathogenic variants in the nonclustered PCDH12 in DMJD. Global developmental delay with severe cognitive impairment, hypotonia, dysmorphic facies, microcephaly, spasticity, and seizures were among the common features. MRI studies obtained in affected individuals show a poorly defined diencephalic-mesencephalic junction with a characteristic malformation of the midbrain on axial sections. Additional imaging features include thinned corpus callosum and supratentorial calcifications.
Recently, a founder allele in PCDH12 was identified in Palestinian families with congenital microcephaly and intracranial calcifications, mimicking a congenital infection. 20, 21 The phenotype was reported similar to "intracranial calcifications with congenital microcephaly," which those investigators grouped with recessive conditions attributed to pathogenic variants in a tight junction component, occludin (OCLN ; MIM#251290) 30 or junctional adhesion molecule 3 (JAM3; MIM#613730). 31 Here, we report that patients with PCDH12 pathogenic variants not only present with calcifications and congenital microcephaly, but also abnormalities in white matter tracts. Consistent with these observations, we found PCDH12 expression in both neural and endothelial cells. We performed brain MR tractography studies on a family with OCLN-related microcephaly and found no evidence of white matter defects, suggesting that the neural phenotype is not an obligate part of the brain calcification spectrum of conditions (not shown). Further studies are required to understand the precise role of PCDH12 in brainstem development, or cross-talk between neurons and blood vessels during neural circuit formation. In DMJD, MR tractography studies evidenced the CST originating within the cortex, but then failed to project through the ventral forebrain to reach the level of the brainstem, suggesting that the butterfly sign reflects a brainstem malformation with its origins in failed cortical projections. We identified additional patients with PCDH12 pathogenic variants presenting with brainstem malformations, severe spasticity accompanied by paralysis, motor incoordination, and thinned corpus callosum, suggesting a generalized disruption of axonal tract formation. Development of mature axon tracts requires that axons navigate to find specific targets, but also that axons have a continuous outgrowth in order to reach the target. A defect in either event could result in abnormal tracts. Here, we found defective neurite growth attributed to loss of PCDH12 in NPCs derived from affected individuals. Therefore, we propose that individuals carrying PCDH12 pathogenic variants display abnormalities in white matter tracts, possibly attributed to defects in neurite outgrowth. This is in agreement with extensive literature showing that nonclustered protocadherins play roles in neurite outgrowth. PCDH7, PCDH10, PCDH17, PCDH18, and PCDH20 mediate axon growth and extension. [32] [33] [34] [35] Moreover, PCDH7, PCDH8, and PCDH10 are implicated in dendritic spine and synapse density 36 and PCDH20 in conferring neuronal positioning. 29 Understanding the roles of the family of nonclustered protocadherins in brain development will require further study and the use of different models, including iPSCs. Our data add PCDH12 to the members of nonclustered protocadherins family involved in the establishment and maintenance of neural circuits during nervous system development. 
